Biomedes Clear science, from bench to bedside

Biomedes

Clear science, from bench to bedside

Latest Articles

The Van, the Letterbox and the Assay: Validating UK Home-Sampling Kits for Real Transit
Medtech Translation

The Van, the Letterbox and the Assay: Validating UK Home-Sampling Kits for Real Transit

Home-sampling kits are moving into mainstream UK diagnostics, but a validation pack that stops at the laboratory bench leaves the most variable preanalytical step unexamined. This article sets out a practical transport-stability protocol for blood and saliva kits, from Royal Mail transit profiles to acceptance criteria and the documentation commissioners will expect.
Version Control for Susceptibility: Making Breakpoint Updates Visible in UK Laboratories
Diagnostics

Version Control for Susceptibility: Making Breakpoint Updates Visible in UK Laboratories

Annual antimicrobial susceptibility updates can reclassify organisms, alter cascade reporting and change clinician behaviour long after the validation paperwork has been filed. This deep dive examines how UK laboratories can manage EUCAST and CLSI revisions across the LIS, disc diffusion, automated systems and stewardship teams without creating invisible reporting inconsistencies.
From Broad Consent to Model Cards: The Biobank Release Audit UK Research Teams Need
Medtech Translation

From Broad Consent to Model Cards: The Biobank Release Audit UK Research Teams Need

Requests to train AI models on biobank tissue and data expose a gap between broad research consent and machine-learning reuse. This release audit sets out the provenance, commercial-use, re-identification and model-documentation checks UK biobanks should complete before samples leave the freezer.
Why 'Normal' Travels Poorly: Local Reference Intervals Before the Next UK Analyzer Replacement
Diagnostics

Why 'Normal' Travels Poorly: Local Reference Intervals Before the Next UK Analyzer Replacement

Vendor reference intervals are convenient defaults, not universal truths. As UK laboratories plan analyzer replacements, local verification and targeted de novo studies can prevent a new platform from redefining disease by configuration.
Rapid Tests, Real-World Conditions: A Commissioner's Checklist for Community Point-of-Care Diagnostics
Diagnostics

Rapid Tests, Real-World Conditions: A Commissioner's Checklist for Community Point-of-Care Diagnostics

Point-of-care testing has moved from the margins of UK diagnostics to something closer to a front door. But a rapid test is not a small laboratory, and scaling community testing depends far less on the device than on the arrangements wrapped around it. A practical checklist for commissioners, pharmacy leads and laboratory teams.
Before the Robot: Why Pathology Automation Should Begin With an Ethnography, Not a Business Case
Medtech Translation

Before the Robot: Why Pathology Automation Should Begin With an Ethnography, Not a Business Case

Vendor throughput claims are measured on a laboratory that does not exist. The informal workarounds and invisible handoffs that hold a real NHS pathology service together are the missing specification — and two weeks of structured observation is cheaper than buying the wrong machine.
The Ninety-Minute Gap: What Really Happens to a Blood Tube Inside the NHS
Diagnostics

The Ninety-Minute Gap: What Really Happens to a Blood Tube Inside the NHS

Between the needle and the result screen sits a chain of handoffs that few clinicians ever see. This explainer follows a single blood tube through a UK pathology network and examines where preanalytical error creeps in — and which interventions actually close the gap.
The False-Positive Problem: Why Sensitivity Alone Should Not Win an NHS Contract
Medtech Translation

The False-Positive Problem: Why Sensitivity Alone Should Not Win an NHS Contract

A test with excellent sensitivity can still generate more false positives than true ones once it meets a low-prevalence population. This analysis works through the arithmetic, draws on UK screening and lateral flow experience, and sets out the questions commissioners should ask before adoption.
Seven Quiet Bottlenecks in UK Medtech Translation - and the Questions That Surface Them Early
Medtech Translation

Seven Quiet Bottlenecks in UK Medtech Translation - and the Questions That Surface Them Early

Promising diagnostics and devices rarely fail on the science alone. They stall in the gaps between prototype, regulation and NHS adoption. Here are seven recurring bottlenecks, with UK-specific warning signs and questions to ask before budgets are committed.
Syndromic Testing at Scale: What UK Laboratories Need to Weigh Before the 2026 Winter Respiratory Surge
Diagnostics

Syndromic Testing at Scale: What UK Laboratories Need to Weigh Before the 2026 Winter Respiratory Surge

Multiplex respiratory panels are moving from specialist virology centres into routine NHS workflows. The science is elegant; the operational questions are harder, from validation and turnaround to antimicrobial stewardship.